These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 32886441)

  • 1.
    Lee H; Eads JR; Pryma DA
    Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on
    Gålne A; Almquist H; Almquist M; Hindorf C; Ohlsson T; Nordenström E; Sundlöv A; Trägårdh E
    J Nucl Med; 2019 Dec; 60(12):1717-1723. PubMed ID: 31000584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Correlation Between [
    Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
    Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Somatostatin Receptor/
    Metser U; Nunez JE; Chan D; Kulanthaivelu R; Murad V; Santiago AT; Singh S
    J Nucl Med; 2024 Oct; 65(10):1591-1596. PubMed ID: 39266292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of somatostatin receptor expressing tumor volume calculated from
    Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of
    Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
    J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pauwels E; Cleeren F; Tshibangu T; Koole M; Serdons K; Boeckxstaens L; Dekervel J; Vandamme T; Lybaert W; den Broeck BV; Laenen A; Clement PM; Geboes K; Cutsem EV; Stroobants S; Verslype C; Bormans G; Deroose CM
    J Nucl Med; 2023 Apr; 64(4):632-638. PubMed ID: 36265911
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined Quantification of
    Lee H; Nakamoto R; Moore SE; Pantel AR; Eads JR; Aparici CM; Pryma DA
    Acad Radiol; 2022 Sep; 29(9):1308-1316. PubMed ID: 34836776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Long-Acting Somatostatin Analogs on 68 Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors.
    Chahid Y; Hashimi K; van de Garde EMW; Klümpen HJ; Hendrikse NH; Booij J; Verberne HJ
    Clin Nucl Med; 2023 Sep; 48(9):757-762. PubMed ID: 37486312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is SUVmax a useful marker for progression-free survival in patients with metastatic GEP-NET receiving
    Teker F; Elboga U
    Hell J Nucl Med; 2021; 24(2):122-131. PubMed ID: 34352047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective head-to-head comparison of
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual and whole-body quantitative analyses of
    Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
    Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
    Adnan A; Basu S
    J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hitherto unknown brain meningioma detected on
    Parghane RV; Talole S; Basu S
    World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative
    Ortega C; Wong RKS; Schaefferkoetter J; Veit-Haibach P; Myrehaug S; Juergens R; Laidley D; Anconina R; Liu A; Metser U
    J Nucl Med; 2021 Oct; 62(10):1406-1414. PubMed ID: 33579805
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Carlsen EA; Johnbeck CB; Binderup T; Loft M; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
    J Nucl Med; 2020 Oct; 61(10):1491-1497. PubMed ID: 32111685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.